SCHEMBL4277299

SCHEMBL4277299

COc1ccc(-c2oc3cc(OC)c(OC)c(OC)c3c(=O)c2OC)cc1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 3/20 0.76
SLC22A2 O15244 1/20 0.76
SLC22A1 O15245 1/20 0.76
ALDH1A1 P00352 4/20 0.66
MEN1 O00255 4/20 0.66
KMT2A Q03164 4/20 0.66
ABCG2 Q9UNQ0 5/20 0.65
CYP3A4 P08684 3/20 0.65
ABCB1 P08183 3/20 0.65
MAPT P10636 2/20 0.65
TUBB4A P04350 1/20 0.65
TUBB P07437 1/20 0.65
TUBA3C P0DPH7 1/20 0.65
PKM P14618 1/20 0.65
XDH P47989 1/20 0.65
TUBA1B P68363 1/20 0.65
TUBA4A P68366 1/20 0.65
TUBB4B P68371 1/20 0.65
TUBB3 Q13509 1/20 0.65
TUBB2A Q13885 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1764300 0.88 ABCG2 (0.73) ADORA3SLC22A2SLC22A1ALDH1A1MEN1
SCHEMBL5073336 0.88 ABCG2 (0.84) ADORA3SLC22A2SLC22A1MEN1KMT2A
SCHEMBL2727281 0.88 ABCG2 (0.83) ADORA3SLC22A2SLC22A1ALDH1A1MEN1
SCHEMBL774317 0.88 ADORA3 (0.72) ADORA3SLC22A2SLC22A1ALDH1A1MEN1
SCHEMBL29549851 0.87 ALDH1A1 (0.60) ADORA3SLC22A2SLC22A1ALDH1A1MEN1
Tangeretin SCHEMBL23629557 0.87 ALDH1A1 (0.70) ADORA3SLC22A2SLC22A1ALDH1A1MEN1
Tetramethylkaempferol SCHEMBL1664159 0.86 ADORA3 (1.00) ADORA3SLC22A2SLC22A1ALDH1A1MEN1
Hexamethoxyflavone SCHEMBL30232628 0.86 MEN1 (0.74) ALDH1A1MEN1KMT2AABCG2CYP3A4
Hexamethoxyflavone SCHEMBL987569 0.86 MEN1 (0.74) ALDH1A1MEN1KMT2AABCG2CYP3A4
SCHEMBL16894654 0.86 ADORA3 (0.72) ADORA3SLC22A2SLC22A1ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260096569-A1 EDIBLE COATING WITH ANTIMICROBIAL PROPERTIES APEEL TECH INC (US) 2026-04-09 US claimed
EP-4496476-A1 GAS PHASE TREATMENT OF PRODUCE Apeel Technology, Inc. (US) 2025-01-29 EP claimed
WO-2023183341-A1 GAS PHASE TREATMENT OF PRODUCE APEEL TECHNOLOGY, INC. (US) 2023-09-28 WO claimed
EP-4090167-A1 EDIBLE COATING WITH ANTIMICROBIAL PROPERTIES Apeel Technology, Inc. (US) 2022-11-23 EP claimed
US-20220330565-A1 EDIBLE COATING WITH ANTIMICROBIAL PROPERTIES APEEL TECHNOLOGY, INC. 2022-10-20 US claimed
WO-2022217089-A1 EDIBLE COATING WITH ANTIMICROBIAL PROPERTIES APEEL TECHNOLOGY, INC. (US) 2022-10-13 WO claimed
US-20260096569-A1 EDIBLE COATING WITH ANTIMICROBIAL PROPERTIES APEEL TECH INC (US) 2026-04-09 US disclosed
US-20250204541-A1 GAS PHASE TREATMENT OF PRODUCE APEEL TECHNOLOGY, INC. 2025-06-26 US disclosed
WO-2025024302-A1 EDIBLE COATING COMPOSITIONS APEEL TECHNOLOGY, INC. (US) 2025-01-30 WO disclosed
EP-4496476-A1 GAS PHASE TREATMENT OF PRODUCE Apeel Technology, Inc. (US) 2025-01-29 EP disclosed
WO-2024107841-A1 EDIBLE COATING COMPOSITIONS APEEL TECHNOLOGY, INC. (US) 2024-05-23 WO disclosed
US-20240156117-A1 EDIBLE COATING COMPOSITIONS APEEL TECH INC (US) 2024-05-16 US disclosed
CN-117769354-A Barrier film composition 阿比尔技术公司 2024-03-26 CN disclosed
WO-2022212597-A1 BARRIER FILM COMPOSITION APEEL TECHNOLOGY, INC. (US) 2022-10-06 WO disclosed
US-20220312803-A1 EDIBLE BARRIER FILM COMPOSITION APEEL TECHNOLOGY, INC. 2022-10-06 US disclosed
WO-2022212556-A1 EDIBLE BARRIER FILM COMPOSITION APEEL TECHNOLOGY, INC. (US) 2022-10-06 WO disclosed
CN-113874052-A Method for preventing calcific deposit formation and inactivating xenoantigen in biological matrices 生物相容性创新责任有限公司 2021-12-31 CN disclosed
US-20180042899-A1 Method of Treating Transplant Rejection and Autoimmune Diseases NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2018-02-15 US disclosed
US-20140050694-A1 Method of Treating Transplant Rejection and Autoimmune Diseases WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2014-02-20 US disclosed
US-20090269772-A1 SYSTEMS AND METHODS FOR IDENTIFYING COMBINATIONS OF COMPOUNDS OF THERAPEUTIC INTEREST THERASIS, INC. 2009-10-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260096569-A1 EDIBLE COATING WITH ANTIMICROBIAL PROPERTIES CYP51A1, ERG28, NISCH ADORA3 2041/4885SLC22A2 1401/4885SLC22A1 1397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.